Published: Wed, March 14, 2018
Medical | By Johnnie Horton

Sarepta Therapeutics (SRPT) PT Set at $81.00 by Credit Suisse Group


After a recent check, the 14-day RSIfor Revive Therapeutics Ltd (RVV.V) is now at 48.91, the 7-day stands at 57.54, and the 3-day is sitting at 68.27.

Today, HC Wainwright raised its price target on Sarepta Therapeutics (NASDAQ:SRPT) to per share. Therefore 81% are positive. The current share price indicates that stock is -42.24% away from its one year high and is moving 30.31% ahead of its 52-week low. After the latest check-in, company stock is 0.84% off of the 50 day high and 59.63% away from the 50 day low price.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $75.77. Needham maintained it with "Buy" rating and $75.0 target in Thursday, October 26 report. It improved, as 24 investors sold Sarepta Therapeutics, Inc. shares while 27 reduced holdings. (NASDAQ:SRPT). Schwab Charles Investment Mngmt owns 268,553 shares or 0.01% of their USA portfolio. As per Tuesday, January 19, the company rating was downgraded by RBC Capital Markets. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Friday, December 16. RBC Capital Markets maintained the shares of SRPT in report on Friday, October 28 with "Outperform" rating. This based on a 1-5 numeric scale where Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell. The rating was maintained by Roth Capital on Thursday, September 3 with "Buy". Independent Research downgraded the stock to "Hold" rating in Wednesday, December 7 report. The firm has "Neutral" rating by Buckingham Research given on Wednesday, August 2. Emerald Mutual Fund Advisers Tru has 1.36% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has "Overweight" rating given on Tuesday, March 6 by Morgan Stanley. The firm has "Neutral" rating by UBS given on Thursday, October 19. The stock decreased 0.94% or $1.02 during the last trading session, reaching $106.94. About 70,952 shares traded. One Liberty Properties, Inc. It has underperformed by 15.45% the S&P500. Cornerstone Management Holdings Limited Liability Corporation owns 2,600 shares. 137.76 million shares or 2.31% less from 141.01 million shares in 2017Q2 were reported. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by ($0.05). The New York-based Salzhauer Michael has invested 0.35% in the stock. The Osterweis Capital Management Inc holds 98,925 shares with $4.49M value, down from 112,900 last quarter. The TSXV listed company saw a recent bid of $0.34 and 2210000 shares have traded hands in the session. Pura Vida Investments Llc acquired 20,000 shares as Sarepta Therapeutics Inc (SRPT)'s stock rose 22.49%.

Pura Vida Investments Llc increased Sarepta Therapeutics Inc (SRPT) stake by 66.67% reported in 2017Q3 SEC filing. It has outperformed by 80.12% the S&P500.

Fire destroys Cranbourne East after-school care facility
The fire started when one of the buildings caught fire at about 1pm at the Blue Hills Retirement Village in Cranbourne East. Emergency services, including eight crews from the CFA and police, are now on-scene and still fighting the flames.

Since October 3, 2017, it had 0 buys, and 1 sale for $575,000 activity. It increased, as 24 investors sold SRPT shares while 27 reduced holdings.

If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it. The S&P 500 index fell 3.55 points, or 0.1%, to 2,783.02, with the industrials sector shedding more than 1.2%. Sigma Planning has 21,350 shares for 0.08% of their portfolio. Columbus Circle Investors stated it has 121,758 shares or 0.09% of all its holdings. Ls Advsr Ltd Liability Corporation owns 1,807 shares for 0% of their portfolio. C WorldWide Group Holding A S raised its holdings in Sarepta Therapeutics by 0.8% during the 3rd quarter. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since March 12, 2017 and is uptrending. (NASDAQ:SRPT) for 8,300 shares. (NASDAQ:SRPT). California State Teachers Retirement System accumulated 94,770 shares or 0.01% of the stock. Parametric Portfolio Associate Ltd Liability Co has 0% invested in Meridian Bioscience, Inc. The institutional investor held 150,000 shares of the health care company at the end of 2017Q3, valued at $6.80 million, down from 383,047 at the end of the previous reported quarter. The stock of Meridian Bioscience, Inc.

Revive Therapeutics Ltd (RVV.V) has a 14-day ATR of 0.03. Driehaus Mngmt Limited Company holds 0.13% of its portfolio in Sarepta Therapeutics, Inc. Cubist Systematic Strategies Lc holds 1,786 shares or 0% of its portfolio. Sarepta Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $68.73.

Sarepta Therapeutics, Inc.is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Like this: